INmune Bio, Inc. Receives Approximately $6.4 Million in Research and Development Rebates from Australia and the United Kingdom
February 08, 2023 08:45 ET
|
INmune Bio, Inc.
BOCA RATON, Fla., Feb. 08, 2023 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s...
Trastuzumab-Resistant HER2 Positive Breast Cancer Reversed By Treatment with INB03
December 11, 2018 08:30 ET
|
INmune Bio, Inc.
Study Results Presented at San Antonio Breast Cancer Symposium 2018 LA JOLLA, Calif., Dec. 11, 2018 (GLOBE NEWSWIRE) -- INmune Bio, Inc., an immunotherapy company developing treatments to...